Line 2,156: |
Line 2,156: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||HD|| || | + | |[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| || |
| |NEW (No Prior) | | |NEW (No Prior) |
| |NEW (No Prior) | | |NEW (No Prior) |
Line 2,170: |
Line 2,170: |
| | | | | |
| | | | | |
− | |HD | + | |SK |
| | | | | |
| | | | | |
Line 2,206: |
Line 2,206: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS | + | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); |
| + | Michelle Don, MD, MS |
| |3/17/24 | | |3/17/24 |
| |6/30/24 | | |6/30/24 |
Line 2,312: |
Line 2,313: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||PENDING | + | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| |
| | || || || ||SK|| || | | | || || || ||SK|| || |
| |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | | |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract |
Line 2,347: |
Line 2,348: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||PENDING | + | |[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease|| |
| | || || || ||SK|| || | | | || || || ||SK|| || |
| |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) |
Line 2,355: |
Line 2,356: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Michelle Don, MD, MS | + | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); |
| + | Michelle Don, MD, MS |
| |3/19/24 | | |3/19/24 |
| |6/30/24 | | |6/30/24 |
Line 2,391: |
Line 2,393: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||PENDING | + | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease|| |
| | || || || ||SK|| || | | | || || || ||SK|| || |
| |Breast Implant-Associated Anaplastic Large Cell Lymphoma | | |Breast Implant-Associated Anaplastic Large Cell Lymphoma |
Line 2,399: |
Line 2,401: |
| | | | | |
| |- | | |- |
− | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD ||7/28/2023 | + | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 |
| | ||Pending|| ||SK|| ||prior authors not available | | | ||Pending|| ||SK|| ||prior authors not available |
| |Angioimmunoblastic T-cell Lymphoma | | |Angioimmunoblastic T-cell Lymphoma |
Line 2,415: |
Line 2,417: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||PENDING | + | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| |
| | || || || ||SK|| || | | | || || || ||SK|| || |
| |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype |
Line 2,468: |
Line 2,470: |
| |NEW (No Prior) | | |NEW (No Prior) |
| |- | | |- |
− | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||PENDING | + | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease|| |
− | | || || || ||SK|| || | + | | || || || ||SK|| ||prior authors not available |
| |Systemic EBV-Positive T-cell Lymphoma of Childhood | | |Systemic EBV-Positive T-cell Lymphoma of Childhood |
| |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA |